Meet MAIA’s Scientific Advisors

team

Jerry W. Shay, PhD

Dr. Shay has been a consultant and on multiple scientific advisory boards for companies such as Procter Gamble, Corixa, BioWhitaker, Clontech, Rexahn, Sierra Science and Elizabeth Therapeutics. In addition he helped start Geron Corporation that focuses on telomerase therapeutics; Life Length a commercial telomere length measurement company; and Reata Pharmaceuticals who is developing anti-oxidant/anti-inflammatory modulators for patients with pulmonary hypertension associated with interstitial lung disease.

Dr. Shay received his PhD from the University of Kansas, did postdoctoral training at the University of Colorado in Boulder, and is currently the Vice Chairman of the Department of Cell Biology and the Associate Director of the NCI Designated Harold Simmons Comprehensive Cancer Center at UT Southwestern Medical Center in Dallas.  Dr. Shay is a named inventor on numerous US patents and has received many scientific and teaching awards. Among these he received the AlliedSignal Award for Research on Aging, the American Aging Association Hayflick Award, the Ted Nash Award, the Popular Science “Best of What’s New” Award, and the Ellison Medical Foundation Senior Scholar Award.  Dr. Shay holds the Southland Financial Corporation Distinguished Chair in Geriatric Research and is a Distinguish Professor at UT Southwestern having received the University of Texas Reagent Outstanding Teaching Award, and the Minnie Steven Piper Foundation Professor Award. In 2015 he received the Distinguished Basic Science Educator Award and in 2016 the May Kay Foundation established a Distinguished Professorship in Cancer Research in honor of Dr. Shay. Finally, in 2017 Dr. Shay was awarded the Eunice Kennedy Shriver NIH Alliance Pioneer Award.

Dr. Shay has been noted as a highly influential biomedical researcher as noted by the Institute for Scientific Research and Science Watch, with over 30 issued patents, >500 peer reviewed publications and a citation h-index of 112.

Read More
team

Marc Cox, Ph.D.

Marc Cox, Ph.D. is a Professor in the Department of Biological Sciences, Co-Director of the Toxicology and Cancer Cluster within the Border Biomedical Research Center, Deputy Director of the BUILDing SCHOLARS Center, and Director of the Center for Faculty Leadership and Development at the University of Texas at El Paso. Dr. Cox is a molecular endocrinologist with expertise in intracellular receptor signaling pathways. In addition to identifying, characterizing, and therapeutically targeting steroid hormone receptor regulatory proteins for the treatment of prostate cancer, he also offers expertise in various model systems, including yeast, that prove useful in large-scale toxicity screens, as well as for high throughput screens for novel drug candidates.

Dr. Cox offers expertise in molecular chaperone-mediated stress response and also maintains a wealth of reagents relevant for research in any system and/or disease involving chaperones and the stress response including a wide variety of cancers, neurodegenerative diseases and toxicant-induced cellular stress. As a result Dr. Cox collaborates on a number of projects that are outside of his major research foci. In addition to environmental monitoring and prostate cancer therapeutics, Dr. Cox has published with collaborators in areas as diverse as Alzheimer’s Disease, stress and depression, and chronic pain. In addition to his research accomplishments, Dr. Cox has served on the Executive Committee of the UT System Faculty Advisory Council, as UTEP Faculty Senate President, and serves on a number of university-wide committees that provide leadership and guidance on curriculum assessment for SACS/COC accreditation, academic program assessment, conflict resolution, the Handbook of Operating Procedures, and intellectual property protection.

Read More
team

Mukesh K Nyati, PhD

Professor Nyati has been focused on basic, translational as well as clinical aspects related to EGFR signaling over the last 20 years. Dr. Nyati is working at the Department of Radiation Oncology of the University of Michigan on developing novel therapeutic agents to selectively inhibit active EGFR dimer formation to induce tumor-specific degradation of EGFR. He is a co-founder of DGD Pharmaceuticals, Corp, and its acting Chief Scientific Officer. Dr Nyati received his Ph.D. from the University of Rajasthan, Jaipur, India and post-doctoral training at the Indian Institute of Science, Bangalore, India and at the University of Michigan, Ann Arbor, MI.
team

WAYNE KLOHS

Dr. Klohs has over thirty-five years of experience in the pharmaceutical industry with increasing levels of responsibility held in positions across the drug development and discovery spectrum. He currently consults for numerous biotech and pharma companies focused in oncology after retiring from Astellas Pharma Inc. as a Senior Vice President and Global Therapeutic Head for Oncology.

In five years at Astellas, Dr. Klohs helped build Oncology into a global business with several marketed products including Tarceva® and Xtandi® and helped build a robust oncology pipeline through in-licensing, the acquisition of OSI, and internal discovery. He was responsible for the successful filings of NDAs and MAAs for Xtandi (enzalutamide) and Tarceva (sNDA).  Dr. Klohs’s previous experience includes acting head of Oncology Clinical Sciences at Takeda Global R&D and Executive Director of Oncology Drug Development at Pfizer, Inc.  At Takeda, he led both early and late-stage Development Teams in Oncology, while at Pfizer, he was responsible for Development Teams from mid-Discovery through POC with additional experience in NDA filing of pentostatin/Nipent. Dr. Klohs led development teams at Pfizer and Parke-Davis to more than 14 successful IND filings and Phase 1 starts as well as leading late stage programs in biologics including monoclonal antibodies and an oncolytic adenovirus.  Prior to his experience in drug development for oncology, he led discovery efforts at Warner-Lambert/Parke Davis Pharmaceutical Research in oncology for 16 years in a number of areas including antiangiogenic agents, multiple drug resistance, histone deacetylase inhibitors, and antifolates.

Read More